Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq’s Minimum Bid Price Rule

NEW YORK, Jan. 9, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (Nasdaq: IMNP) (“Immune”), announced today that it intends to request a hearing before the Nasdaq Listing Qualifications Staff Panel to appeal a notification that Immune’s securities are subject to delisting from The Nasdaq Capital Market (“Nasdaq”). Immune will present its plan at the upcoming hearing to…